Option Care Health, Inc. (NASDAQ:OPCH) Receives $29.86 Consensus Target Price from Analysts

Shares of Option Care Health, Inc. (NASDAQ:OPCH) have earned an average recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $29.86.

Several analysts have recently weighed in on OPCH shares. Barrington Research lifted their target price on Option Care Health from $32.00 to $33.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 14th. Truist Financial decreased their price objective on Option Care Health from $41.00 to $34.00 and set a “buy” rating for the company in a report on Friday, November 1st. UBS Group began coverage on Option Care Health in a report on Thursday, December 5th. They issued a “neutral” rating and a $26.00 price objective for the company. Bank of America upgraded Option Care Health from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $26.00 to $33.00 in a report on Monday, January 13th. Finally, JMP Securities restated a “market outperform” rating and issued a $30.00 price objective (down from $31.00) on shares of Option Care Health in a report on Friday, January 10th.

Option Care Health Stock Down 0.5 %

Shares of OPCH opened at $29.31 on Friday. The company has a market cap of $4.99 billion, a PE ratio of 24.63, a P/E/G ratio of 2.09 and a beta of 1.31. The business has a fifty day moving average of $23.96 and a 200 day moving average of $27.77. Option Care Health has a 52-week low of $21.39 and a 52-week high of $34.63. The company has a quick ratio of 1.32, a current ratio of 1.73 and a debt-to-equity ratio of 0.77.

Insider Transactions at Option Care Health

In other Option Care Health news, Director Harry M. Jansen Kraemer, Jr. purchased 43,000 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were acquired at an average price of $22.54 per share, for a total transaction of $969,220.00. Following the completion of the purchase, the director now owns 326,334 shares of the company’s stock, valued at approximately $7,355,568.36. The trade was a 15.18 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.64% of the company’s stock.

Institutional Investors Weigh In On Option Care Health

Large investors have recently modified their holdings of the business. UMB Bank n.a. boosted its position in Option Care Health by 41.7% in the fourth quarter. UMB Bank n.a. now owns 1,176 shares of the company’s stock valued at $27,000 after buying an additional 346 shares during the last quarter. GAMMA Investing LLC boosted its position in Option Care Health by 110.6% in the third quarter. GAMMA Investing LLC now owns 897 shares of the company’s stock valued at $28,000 after buying an additional 471 shares during the last quarter. Lindenwold Advisors INC boosted its position in Option Care Health by 5.4% in the third quarter. Lindenwold Advisors INC now owns 9,548 shares of the company’s stock valued at $299,000 after buying an additional 489 shares during the last quarter. Pacer Advisors Inc. boosted its position in Option Care Health by 2.2% in the fourth quarter. Pacer Advisors Inc. now owns 25,483 shares of the company’s stock valued at $591,000 after buying an additional 537 shares during the last quarter. Finally, Sheets Smith Wealth Management boosted its position in Option Care Health by 2.4% in the fourth quarter. Sheets Smith Wealth Management now owns 23,856 shares of the company’s stock valued at $553,000 after buying an additional 550 shares during the last quarter. Hedge funds and other institutional investors own 98.05% of the company’s stock.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.